Advances or Review and Antigen and Saccharide and Conjugation and Linkers

Dr. Funda Meric-Bernstam

The development of antibody–drug conjugates (ADCs) equally anticancer therapies continues to evolve. The first ADC was canonical by the U.S. Food and Drug Administration (FDA) in 2000,^one followed by a long menstruum without whatever regulatory approvals for this class of drugs (Tabular array i). These are exciting times in the field, as four new agents^two-5 take been canonical in the last year. The Educational activity Session "Antibody–Drug Conjugates: The Strength Awakens," presented during the ASCO20 Virtual Education Program, discussed the development of ADCs and the targets and payloads currently under investigation for utilise in a diversity of cancers. The session was chaired past Funda Meric-Bernstam, Doc, of The University of Texas Md Anderson Cancer Center.

Table 1. FDA-Canonical Antibiotic–Drug Conjugates for Cancer Treatment

View larger

Development of ADCs

Anthony W. Tolcher, Doc, FRCPC, FACP, FASCO, of Texas Oncology, provided an overview of the development of ADCs over time. The development of whatsoever drug is no uncomplicated matter, and it is even more than complex for ADCs. All 4 components of an ADC (antigen, antibody, linker, and cytotoxic payload) require optimization. Additionally, the ADC mechanistic pathway consists of a complicated sequence of events. These include the ADC in plasma binding to the target antigen, the ADC–antigen complex internalized into the target cell, the release of the cytotoxic agent, and jail cell bike arrest and death. Ensuring that each step occurs consistently is very challenging, and pathway complexity is the main reason so many previous attempts take been unsuccessful.

"Over 100 agents, I believe, have entered the clinic at one fourth dimension or another over the concluding 25 years, and well-nigh of those agents have failed," Dr. Tolcher said.

"Over 100 agents, I believe, take entered the clinic at one time or another over the last 25 years, and most of those agents have failed." - Dr. Anthony Due west. Tolcher

Researchers have used the data from earlier agents to better ADC efficacy and rubber. Target antigens are typically tumor-associated, meaning they are as well institute on normal cells. Expression on normal cells serves as an antigen sink, leading to less drug delivered to the tumor and more toxicity. Off-target toxicity may potentially be improved by administering naked antibody earlier treatment with the ADC. Boosting antitumor activity may also be possible by increasing payload potency (e.g., pyrrolobenzodiazepine and NBE-002) or increasing the drug–antibiotic ratio (e.chiliad., trastuzumab deruxtecan and XMT-1536).

In the by, solubilizing antimicrotubule payloads were often called due to their high say-so. Unfortunately, the majority of solid tumors are not sensitive to these agents, limiting their clinical utility.

Dr. Anthony West. Tolcher

"Using this form of compounds to endeavour to treat broader malignancies has, I think, been at least in part responsible for the failure of so many ADCs," Dr. Tolcher said.

The two most recently approved drugs (trastuzumab deruxtecan and sacituzumab govitecan)^four,5 incorporated topoisomerase I payloads. Additional ADCs in evolution employ a more diverse array of payloads, with mechanisms of action across cytotoxicity. These include agents using apoptotic payloads, stimulator of interferon genes payloads, and HER2 with cost-like receptor agonist payloads. Centyrin and alphalex–peptide payload delivery systems are too beingness investigated.

New Targets, New Payloads

Amita Patnaik, MD, FRCPC, of Offset Center for Cancer Intendance, reviewed novel ADC targets and payloads. Antigens in ADCs are frequently non tumor-specific and may be expressed in good for you tissue, leading to off-target distribution of the ADC and decreased efficacy.

"Target option is perhaps one of the almost disquisitional issues in ADC development," Dr. Patnaik said.

Dr. Amita Patnaik

Characteristics of an platonic target include loftier, homogenous, and sectional expression on tumor cells; footling to no antigen shedding; internalization capability; and high expression inside the tumor only piffling to no expression in healthy cells.

Many dissimilar targets are currently being evaluated in clinical and preclinical development. These include targets associated with driver oncogenes, overexpressed in cancer cells or occurring in the tumor microenvironment, and targets involving stem cells. Dr. Patnaik reviewed some of the ADC trials presented at contempo oncology meetings (Table 2^6-12), as well as ADCs in evolution with novel payloads and immunomodulatory payloads (Table 3^13-21).

Table 2. Antibody–Drug Conjugates With Novel Targets in Evolution

View larger

Table iii. Antibody–Drug Conjugates With Novel Payloads in Development

View larger

"With and then many ADCs in clinical development and the unprecedented approvals of the by yr, it'southward clear that ADCs volition continue to exist a critical part of the therapeutic armamentarium against cancer. Maximizing therapeutic index through clinical and translational approaches will exist necessary to move the field forward," Dr. Patnaik said.

"With so many ADCs in clinical development and the unprecedented approvals of the by year, information technology's articulate that ADCs will go on to be a critical office of the therapeutic armamentarium against cancer."-- Dr. Amita Patnaik

Overcoming Challenges in ADC Therapy

Dr. Meric-Bernstam discussed remaining challenges in ADC therapy, particularly regarding patient selection. In that location are many unanswered questions, including how much target expression is needed, the impact of histology and payload/linkers, and whether mutations are a target for ADCs. During the early on phases of evolution, assays approved by Clinical Laboratory Improvement Amendments may non notwithstanding exist available. In improver, specific data is ofttimes lacking about the target: the best assay, the correlation betwixt RNA and protein, cutoffs for target expression, poly peptide part, intratumoral and intertumoral heterogeneity, and how expression is affected by tumor progression and other therapies.

Conducting trials of ADCs comes with operational challenges, especially in selecting advisable patients.

"Trials are hindered past the inability to rapidly identify patients overexpressing the targets of involvement," Dr. Meric-Bernstam said. "Many trials either enroll patients without biomarker testing or they add biomarker screening, which may add filibuster into starting therapy [and is] especially challenging when the target is not frequently expressed."

Clinical trials of ADCs are often conducted in diseases that are more common or those where the target antigen is more oftentimes expressed.

As more ADCs become available, handling selection for individual patients volition need to consider the relative target expression or likelihood of expression, target heterogeneity, the efficacy and adverse event profile of the ADC, payload sensitivity, previous treatment history, and the patient's preferences and comorbidities.

"Nosotros need to understand better how to optimally select and assess target agent expression, the threshold needed for target antigen expression, the bear upon of intratumor heterogeneity, and whether this can exist overcome with a bystander effect," Dr. Meric-Bernstam said. "Farther, we demand strategies for multiplex screening for optimal treatment option every bit well as rational combination therapy."

— Muriel Cunningham

References

1. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and prophylactic of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in kickoff relapse. J Clin Oncol. 2001 Jul one;19(13):3244-3254.
2. Sehn LH, Herrera AF, Flowers CR, et al. Polatuzumab vedotin in relapsed or refractory diffuse big B-cell lymphoma. J Clin Oncol. 2020 Jan 10;38(2):155-165.
3. Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death one/programmed death ligand 1 therapy. J Clin Oncol. 2019 October 10;37(29):2592-2600.
4. Modi Due south, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. Northward Engl J Med. 2020 Feb 13;382(7):610-621.
5. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741-751.
6. Janne PA, Yu HA, Johnson ML, et al. Prophylactic and preliminary antitumor action of U3-1402: a HER3-targeted antibody drug cohabit in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 2019 May 20;37(suppl fifteen):9010.
7. Yonemori K, Masuda North, Takahashi S, et al. Unmarried agent action of U3-1402, a HER3-targeting antibiotic-drug conjugate, in HER3-overexpressing metastatic breast cancer: updated results from a stage I/II trial. Ann Oncol. 2019;30(suppl iii):iii47-iii64.
8. Sandall SL, Mason M, Olson D, et al. SGN-CD228A: a novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors. Cancer Res. 2019 Jul;79(suppl xiii).
9. Gazzah A, Cousin Due south, Boni V, et al. Get-go-in-human phase 1 written report of the antibiotic-drug cohabit (ADC) SAR408701 in advanced solid tumors: dose-expansion cohort of patients (pts) with not-squamous non-small cell lung cancer (NSQ NSCLC). J Clin Oncol. 2019 May;37(suppl 15):9072.
10. Meric-Bernstam F, Boni V, Spira AI, et al. Preliminary results of PROCLAIM-CX-2009, a first-in-human being, dose-finding study of the probody drug conjugate CX-2009 in patients with advanced solid tumors. Cancer Res. 2019;79(13 Suppl):Abstruse nr LB-185.
11. Boni Five, Burris HA, Liu JF, et al. CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the showtime-in-human report in patients (Pts) with advanced cancer including breast cancer (BC). J Clin Oncol. 2020 May 20;38(suppl 15):526.
12. Johnson ML, El-Khoueiry AB, Hafez North, et al. CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a start-in-homo study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer. J Clin Oncol. 2020 May 20;38(suppl 15):3502.
13. Banerji U, van Herpen CML, Saura C, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase one dose-escalation and dose-expansion report. Lancet Oncol. 2019;20:1124-1135.
14. Zammarchi F, Havenith K, Chivers S, et al. Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors. Cancer Res. 2018;78(13 Suppl):Abstract nr 2792A.
15. Flynn MJ, Zammarchi F, Tyrer PC, et al. ADCT-301, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting CD25-expressing hematological malignancies. Mol Cancer Ther. 2016;15:2709-2721.
16. Kahl BS, Hamadani Yard, Radford J, et al. A phase I report of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019;25:6986-6994.
17. Pahl A, Lutz C, Hechler T. Amanitins and their development as a payload for antibody-drug conjugates. Drug Discov Today Technol. 2018;xxx:85-89.
18. Pahl A, Ko J, Breunig C, et al. HDP-101: preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma. J Clin Oncol. 2018;36:15s (suppl; abstr e14527).
19. Bauss F, Lechmann G, Krippendorff BF, et al. Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion poly peptide for lung cancer therapy. Mol Oncol. 2016;10:1317-1329.
20. Alewine C, Ahmad M, Peer CJ, et al. Phase I/Two study of the mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma. Clin Cancer Res. 2020;26:828-836.
21. Moyes K, Brender T, Smith SW, et al. A systemically administered, conditionally agile TLR8 agonist for the treatment of HER2-expressing tumors. Cancer Res. 2019;79(13 Suppl):Abstract nr 3271.

holmanheavow.blogspot.com

Source: https://dailynews.ascopubs.org/do/10.1200/ADN.20.200278/full/

Share this post